Translational pathophysiology: A novel molecular mechanism of human disease

Blood

Volumn 95, Issue 11, 2000, Pages 3280-3288

  Cazzola, Mario ^a   Skoda, Radek C ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ADENOSYLMETHIONINE DECARBOXYLASE; BETA 2 ADRENERGIC RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR; FERRITIN; HELICASE; INITIATION FACTOR; INTERLEUKIN 15; INTERLEUKIN 7; IRON REGULATORY FACTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; RIBOSOME PROTEIN; RNA BINDING PROTEIN; THROMBOPOIETIN;

CATARACT; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERFERRITINEMIA; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RIBOSOME; RNA TRANSLATION; TRANSLATION INITIATION; UNTRANSLATED REGION;

EID: 0034210637     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3280.011k41_3280_3288     Document Type: Review

References (109)

1. Lewin B. Genes VI. Oxford, UK: Oxford University Press; 1997.
2. Semenza GL. Transcriptional regulation of gene expression: mechanisms and pathophysiology. Hum Mutat. 1994;3:180-199.
3. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watsond JD. Molecular Biology of the Cell. New York, NY: Garland Publishing; 1989.
4. Gray NK, Wickens M. Control of translation initiation in animals. Annu Rev Cell Dev Biol. 1998;14: 399-458.
5. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene. 1999;234:187-208.
6. Barabino SM, Keller W. Last but not least: regulated poly(A) tail formation. Cell. 1999;99:9-11.
7. Rao CD, Pech M, Robbins KC, Aaronson SA. The 5′ untranslated sequence of the c-sis/platelet-derived growth factor 2 transcript is a potent translational inhibitor. Mol Cell Biol. 1988;8:284-292.
8. Bernstein J, Sella O, Le SY, Elroy-Stein O. PDGF2/c-sis mRNA leader contains a differentiation-linked internal ribosomal entry site (D-IRES). J Biol Chem. 1997;272:9356-9362.
9. Kim SJ, Park K, Koeller D, et al. Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem. 1992; 267:13702-13707.
10. Grens A, Scheffler IE. The 5′- and 3′-untranslated regions of ornithine decarboxylase mRNA affect the translational efficiency. J Biol Chem. 1990; 265:11810-11816.
11. Manzella JM, Blackshear PJ. Regulation of rat ornithine decarboxylase mRNA translation by its 5′-untranslated region. J Biol Chem. 1990;265: 11817-11822.
12. Theil E. Iron regulatory elements (IREs): a family of mRNA non-coding sequences. Biochem J. 1994;304:1-11
13. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell. 1993;72:19-28.
14. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian protoncoupled metal-ion transporter. Nature. 1997;388: 482-488.
15. Nielsen FC, Ostergaard L, Nielsen J, Christiansen J. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature. 1995;377:358-362.
16. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270.
17. Rogers JT, Leiter LM, McPhee J, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem. 1999;274:6421-6431.
18. Ghilardi N, Wiestner A, Skoda RC. Thrombopoietin production is inhibited by a translational mechanism. Blood. 1998;92:4023-4030.
19. Namen AE, Lupton S, Hjerrild K, et al. Stimulation of B-cell progenitors by cloned murine interteukin-7. Nature. 1988;333:571-573.
20. Bamlord RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci USA. 1996;93:2897-2902.
21. Nishimura H, Washizu J, Nakamura N, Enomoto A, Yoshikai Y. Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. J Immunol. 1998;160:936-942.
22. Arrick BA, Lee AL, Grendell RL, Derynck R. Inhibition of translation of transforming growth factor-beta 3 mRNA by its 5′ untranslated region. Mol Cell Biol. 1991;11:4306-4313.
23. Arrick BA, Grendell RL, Griffin LA. Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol Cell Biol. 1994;14:619-628.
24. Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18:6178-6190.
25. Harigai M, Miyashita T, Hanada M, Reed JC. A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene. 1996;12:1369-1374.
26. Phelps DE, Hsiao KM, Li Y, et al. Coupled transcriptional and translational control of cyclin-dependent kinase inhibitor p18INK4c expression during myogenesis. Mol Cell Biol. 1998;18:2334-2343.
27. Mize GJ, Ruan H, Low JJ, Morris DR. The inhibitory upstream open reading frame from mammalian S-adenosylmethionine decarboxylase mRNA has a strict sequence specificity in critical positions. J Biol Chem. 1998;273:32500-325005.
28. Parola AL, Kobilka BK. The peptide product of a 5′ leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem. 1994;269:4497-4505.
29. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927-1932.
30. Ossipow V, Descombes P, Schibler U. CCAAT/ enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc Natl Acad Sci USA. 1993; 90:8219-8223.
31. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell. 1991;67:569-579.
32. Acland P, Dixon M, Peters G, Dickson C. Subcellular fate of the int-2 oncoprotein is determined by choice of initiation codon. Nature. 1990;343: 662-665.
33. Florkiewicz RZ, Sommer A, Human basic fibroblast growth factor gene encodes four polypeptides: three initiate translation from non-AUG codons. Proc Natl Acad Sci U S A. 1989;86: 3978-3981.
34. Prats H, Kaghad M, Prats AC, et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci U S A. 1989;86:1836-1840.
35. Arnaud E, Touriol C, Boutonnet C, et al. A new 34-kilodalton isoform of human fibroblast growth factor 2 is cap dependently synthesized by using a non-AUG start codon and behaves as a survival factor. Mol Cell Biol. 1999;19:505-514.
36. Hann SR, King MW, Bentley DL, Anderson CW, Eisenman RN. A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas. Cell. 1988;52:185-195.
37. Hann SR, Sloan-Brown K, Spotts GD. Translational activation of the non-AUG-initiated c-myc 1 protein at high cell densities due to methionine deprivation. Genes Dev. 1992;6:1229-1240.
38. Carter PS, Jarquin-Pardo M, De Benedetti A. Differential expression of Myc1 and Myc2 isoforms in cells transformed by elF4E: evidence for internal ribosome repositioning in the human c-myc 5′UTR. Oncogene. 1999;18:4326-4335.
39. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991;10:655-664.
40. Packham G, Brimmell M, Cleveland JL. Mammalian cells express two differently localized Bag-1 isoforms generated by alternative translation initiation. Biochem J. 1997;328:807-813.
41. Yang X, Pater A, Tang SC. Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants. Oncogene. 1999;18:4546-4553.
42. Kozak M. Interpreting cDNA sequences: some insights from studies on translation. Mamm Genome. 1996;7:563-574.
43. Miller PF, Hinnebusch AG: cis-Acting sequences involved in the translational control of GCN4 expression. Biochim Biophys Acta. 1990;1050: 151-154.
44. Ruan H, Shantz LM, Pegg AE, Morris DR. The upstream open reading frame of the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive translational control element. J Biol Chem. 1996;271:29576-29582.
45. Cao J, Geballe AP. Inhibition of nascent-peptide release at translation termination. Mol Cell Biol. 1996;16:7109-7114.
46. Su MA, Trenor CC, Fleming JC, Fleming MD, Andrews NC. The G185R mutation disrupts function of the iron transporter Nramp2. Blood. 1998;92: 2157-2163.
47. Zhou XY, Tomatsu S, Fleming RE, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A. 1998;95:2492-2497.
48. Fleming RE, Migas MC, Zhou X, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. Proc Natl Acad Sci U S A. 1999; 96:3143-3148.
49. Rouault TA, Hentze MW, Halle DJ, Harford JB, Klausner RD. The iron-responsive element binding protein: a method for the affinity purification of a regulatory RNA-binding protein. Proc Natl Acad Sci U S A. 1989;86:5768-5772.
50. Haile DJ, Hentze MW, Rouault TA, Harford JB, Klausner RD. Regulation of interaction of the iron-responsive element binding protein with iron-responsive RNA elements. Mol Cell Biol. 1989;9: 5055-5061.
51. Samaniego F, Chin J, Iwai K, Rouault TA, Klausner RD. Molecular characterization of a second iron-responsive element binding protein, iron regulatory protein 2: structure, function, and post-translational regulation. J Biol Chem. 1994;269: 30904-30910.
52. Gray NK, Hentze MW. Iron regulatory protein prevents binding of the 43S translation pre-initiation complex to ferritin and eALAS mRNAs. EMBO J. 1994;13:3882-3891.
53. Muckenthaler M, Gray NK, Hentze MW. IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex elF4F. Mol Cell. 1998;2:383-388.
54. Haile DJ, Rouault TA, Tang CK, Chin J, Harford JB, Klausner RD. Reciprocal control of RNA-binding and aconitase activity in the regulation of the iron-responsive element binding protein: role of the iron-sulfur cluster. Proc Natl Acad Sci U S A. 1992;89:7536-7540.
55. Iwai K, Drake SK, Wehr NB, et al. Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc Natl Acad Sci U S A. 1998;95:4924-4928.
56. Rogers JT. Ferritin translation by interleukin-6: the role of sequences upstream of the start codons of the heavy and light subunit genes. Blood. 1996;87:2525-2537
57. Girelli D, Oliviero O, De Franceschi L, Corrocher R, Bergamaschi G, Cazzola M. A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol. 1995;90:931-934.
58. Bonneau D, Winter-Fuseau I, Loiseau M-N, et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder? J Med Genet. 1995; 32:778-779.
59. Beaumont C, Leneuve P, Devaux I, et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nature Genet. 1995;11: 444-446.
60. Girelli D, Corrocher R, Bisceglia L, et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). Blood. 1995;86: 4050-4053.
61. Aguilar-Martinez P, Biron C, Masmejean C, Jeanjean P, Schved J-F. A novel mutation in the iron responsive element of ferritin I-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome [letter]. Blood. 1996;88:1895.
62. Merkt J. Hereditary hyperferritinemia-cataract syndrome. Dtsch Med Wochenschr. 1997;122: 504-506.
63. Cazzola M, Bergamaschi G, Tonon L, et al. Hereditary hyperferritinemia-cataract syndrome: relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA. Blood. 1997;90:814-821.
64. Girelli D, Corrocher R, Bisceglia L, et al. Hereditary hyperferritinemia-cataract syndrome caused by a 29-base pair deletion in the iron responsive element of ferritin L-subunit gene. Blood. 1997; 90:2084-2088.
65. Arnold JD, Mumford AD, Lindsay JO, Hegde U, Hagan M, Hawkins JR. Hyperferritinaemia in the absence of iron overload. Gut. 1997;41:408-410.
66. Martin ME, Fargion S, Brissot P, Pellat B, Beaumont C. A point mutation in the bulge of the iron-responsive element of the L ferritin gene in two families with the hereditary hyperferritinemia-cataract syndrome. Blood. 1998;91:319-323.
67. Mumford AD, Vulliamy T, Lindsay J, Watson A. Hereditary hyperferritinemia-cataract syndrome: two novel mutations in the L-ferritin iron-responsive element [letter]. Blood. 1998;91:367-369.
68. Cicilano M, Zecchina G, Roetto A, et al. Recurrent mutations in the IRE of L-ferritin in hereditary hyperferritinemia-cataract syndrome. Haematologica. 1999;84:489-492.
69. Balas A, Aviles MJ, Garcia-Sanchez F, Vicario JL. Description of a new mutation in the L-ferrin iron-responsive element associated with hereditary hyperferritinemia-cataract syndrome in a Spanish family [letter]. Blood. 1999;93:4020-4021.
70. Cremonesi L, Fumagalli A, Soriani N, et al. Development of a DG-DGGE method for rapid mutational scanning in ferritin L-chain IRE: an approach for screening of hereditary hyperferritinemia cataract syndrome (HHCS) [abstract]. Proceedings of the World Congress on Iron Metabolism. Sorrento, Italy; 1999:164.
71. Beaumont C, Milon B, Hetet G. Genetic studies on patients with elevated serum ferritin levels and no iron overload: evaluation at a two year recruitment [abstract]. Proceedings of the World Congress on Iron Metabolism. Sorrento, Italy; 1999:161.
72. Brools DG, Stamboliam DE. A novel mutation of the "bulge cytosine" in the human L ferritin iron responsive element causes hyperferritinemia/ cataract syndrome [abstract]. Proceedings of the World Congress on Iron Metabolism. Sorrento, Italy; 1999:163.
73. Kato GJ, Casella F. L-ferritin-Baltimore-1: a novel mutation in the iron response element (C32G) as a cause of the hyperferritinemia-cataract syndrome [abstract]. Blood. 1999;94:407a.
74. Girelli D, Zecchina G, Tinazzi E, et al. Molecular, biochemical and clinical findings in a series of families with the hereditary hyperferritinemia-cataract syndrome. [abstract]. Blood. 1999; 94:644a.
75. Allerson CR, Cazzola M, Rouault TA. Clinical severity and thermodynamic effects of iron-responsive element mutations in hereditary hyperferritinemia-cataract syndrome. J Biol Chem. 1999; 274:26439-26447.
76. Levi S, Girelli D, Perrone F, et al. Analysis of ferritins in lymphoblastoid cell lines and in the lens of subjects with hereditary hyperferritinemia-cataract syndrome. Blood. 1998;91:4180-4187.
77. Arosio C, Fossati L, Vigano M, Trombini P, Cazzaniga G, Piperno A. Hereditary hyperferritinemia cataract syndrome: a de novo mutation in the iron responsive element of the L-ferritin gene. Haematologica. 1999;84:560-561.
78. Luukkonen BG, Tan W, Schwartz S. Efficiency of reinitiation of translation on human immunodeficiency virus type 1 mRNAs is determined by the length of the upstream open reading frame and by intercistronic distance. J Virol. 1995;69: 4086-4094.
79. Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339:746-754.
80. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87: 567-573.
81. Cohen-Solal K, Villeval JL, Titeux M, Lok S, Vainchenker W, Wendling F. Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood. 1996;88: 2578-2584.
82. Schlemper RJ, van der Maas APC, Eikenboom JCJ. Familial essential thrombocythemia: clinical characteristics of 11 cases in one family. Ann Hematol. 1994;68:153-158.
83. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nature Genet. 1998; 18:49-52.
84. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood. 1998;92:1091-1096.
85. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocytosis through a mechanism of more efficient translation of TPO mRNA [letter]. Blood. 1999;94:1480-1482.
86. Kikuchi M, Tayama T, Hayakawa H, Takahashi I, Hoshino H, Ohsaka A. Familial thrombocytosis. Br J Haematol. 1995;89:900-902.
87. Ghilardi N, Wiestner A, Kikuchi M, Oshaka A, Skoda RC. Hereditary thrombocythemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999;107:310-316.
88. Jorgensen MJ, Raskind WH, Wolff JF, Bachrach HR, Kaushansky K. Familial thrombocytosis associated with overproduction of thrombopoietin due to a novel splice donor site mutation [abstract]. Blood. 1998;92:205a
89. Fickers M, Speck B. Thrombocythaemia: familial occurrence and transition into blastic crisis. Acta Haematol. 1974;51:257-265.
90. Slee PHTJ, van Everdingen JJE, Geraedts JPM, te Velde J, den Ottolander GJ. Familial myeloproliterative disease. Acta Med Scand. 1981;210: 321-327.
91. Eyster ME, Saletan SL, Rabellino EM, et al. Familial essential thrombocythemia. Am J Med. 1986;80:497-502.
92. Fernandez-Robles E, Vermylen C, Martial P, Ninane J, Cornu G. Familial essential thrombocythemia. Pediatr Hematol Oncol. 1990;7:373-376.
93. Janssen JW, Anger BR, Drexler HG, Bartram CR, Heimpel H. Essential thrombocythemia in two sisters originating from different stem cell levels. Blood. 1990;75:1633-1636.
94. Yagisawa M, Kamizaki K, Nagase T, et al. Familial essential thrombocythemia in a daughter and mother [in Japanese]. Nippon Naika Gakkai Zasshi. 1990;79:531-532
95. Williams EC, Shahidi NT. Benign familial thrombocytosis. Am J Hematol. 1991;37:124-125.
96. Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46:225-229.
97. Ulibarrena C, Vecino AM, Odriozola J, Cesar JM. Familial essential thrombocythemia associated with von Willebrand disease [letter]. Med Clin (Barc). 1997;109:237-238.
98. Cohen N, Almoznino-Sarafian D, Weissgarten J, et al. Benign familial microcytic thrombocylosis with autosomal dominant transmission. Clin Genet. 1997;52:47-50.
99. Kunishima S, Mizuno S, Naoe T, Saito H, Kamiya T. Genes for thrombopoietin and c-mpl are not responsible for familial thrombocythaemia: a case study. Br J Haematol. 1998;100:383-386.
100. McKusick VA et al. OMIM (database, online). Melanoma, cutaneous malignant; CMM. Developed by National Center for Biotechnology Information. Available at http://www3.ncbi.nlm.nih.gov/ htbin-post/Omim/dispmim?155600. Accessed March 13, 2000.
101. McKusick VA et al. OMIM. Cyclin-dependent kinase inhibitor-2A; CDKN2A. Developed by National Center for Biotechnology Information. Available at http://www.ncbi.nlm.nih.gov/htbin-post/ Omim/dispmim?600160. Accessed March 13, 2000.
102. Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer. 1999;25: 339-348.
103. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 1994;8:23-26.
104. Liu L, Dilworth D, Gao L, et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nature Genet. 1999;21:128-132.
105. Picard V, Renaudie F, Porcher C, Hentze MW, Grandchamp B, Beaumont C. Overexpression of the ferritin H subunit in cultured erythroid cells changes the intracellular iron distribution. Blood. 1996;87:2057-2064.
106. Galanello R, Cau M, Melis MA, Deidda F, Cao A, Cazzola M. Studies of Nramp2, transferrin receptor and transferrin genes as candidate genes for human hereditary microcytic anemia due to defective iron absorption and utilization [abstract]. Blood. 1998;92:669a.
107. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
108. Burton JD, Bamford RN, Peters C, et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994;91:4935-4939.
109. Rogers JT, Leiter LM, McPhee J, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences. J Biol Chem. 1999;274:6421-6431.